INTRODUCTION
I interpret my title as meaning organ transplantation. Corneal and skin grafts differ from organ grafts in that they are not vascularised; in the former, immunosuppression is not needed to prevent rejection, while skin is very rapidly rejected unless transplanted as an autograft or between identical twins. Grafts are classified as: autograft, when the transplant is from the same individual, as is usually the situation in skin grafts; isograft, when the donor and recipient are of the same species and have identical genotypesin other words, inbred litter mates or identical twins; allograft, when the donor and recipient are of the same species but their genotypes are different this is the usual situation in human organ transplantation; and xenograft, when donor and recipient are of different species. I will use kidney transplantation as my model and describe it in some detail, not only because it is my own subject, but also because it developed earlier than transplantation of other solid organs.
KIDNEY TRANSPLANTATION Development
Kidney transplantation enjoys a number of advantages over transplantation of other organs. The kidney is a duplicated organ and therefore a living donor can be used. This made it possible to transplant a kidney between identical twins without need for immunosuppression to prevent rejection, and such an isograft was the first successful human organ transplant. The surgery required is straightforward: only one artery, one vein and the ureter of the donor organ need to be anastomosed to the recipient's vessels and bladder. Transplantation of the liver, heart, pancreas and heart -lung are technically much more difficult. The progress of the grafted kidney can easily be monitored by urine volume and simple blood tests. The position of the kidney in the iliac fossa enables it to be visualised easily using imaging techniques such as ultrasound and renography. Rejection, if suspected, can be diagnosed by percutaneous needle biopsy which is a simple procedure; aspiration of a few kidney cells with a fine needle can even be carried out daily. Kidney function can be replaced for long periods by artificial means and the patient restored to relative health by dialysis treatment. And finally, the long experience of kidney transplantation gives it a considerable advantage over that involving other solid organs. It was shown by Ullmann, in a demonstration to a Vienna medical society on 1 March 1902, that when the kidney in a dog was transplanted from its normal site to the vessels in the neck, urine continued to be produced I evidence that urine production does not require a nerve supply. That same year Decastello, at another Vienna hospital, carried out dog-to-dog transplants,2 and these were Carrel , also in Vienna, carried out autografts and later allografts of kidneys in cats and dogs using improved methods of vascular suturing.3 He then removed the recipient animal's own kidneys and found that the animal remained well for a few days, after which urine production ceased. Jaboulay, Carrel's teacher, is credited with the first human transplants.4 He carried out two xenografts, transplanting a pig and a goat kidney into the arm or thigh of patients with chronic renal failure. Each kidney worked for one hour only. Unger, in Berlin in 1909, also attempted xenografts, grafting a stillborn kidney to a baboon, and a kidney from a pig -ape to a young girl, but neither graft produced urine.5 In 1923 Williamson repeated the dog-to-dog experiment at the Mayo Foundation. He described the histological appearance of the failed kidney for the first time.6,7 The first human allografts, that is human -to-human grafts, were carried out by Voronoy in the Ukraine,8 six in all between 1933 and 1949. He used cadaver kidneys but none achieved any useful function. In 1946 a group in Boston carried out a human allograft using arm vessels, but it functioned only briefly. In the early 1950s, the experimental work of Simonsen9' 10 and Dempster" showed that immunological mechanisms were responsible for the rejection of grafts. With this in mind, further attempts to transplant cadaver kidneys were made in Paris by K(Jss,12 Servelle,'3 and Dubost,'4 and in Boston by Hume and colleagues15 usually without using immunosuppression though small doses of ACTH or cortisone were given to some patients. Surprisingly, the kidney survived for a time in a few cases and this was attributed to the relative immunosuppression of uraemia. During this period it became clear that it was better to place the transplanted kidney in the pelvis than superficially in the thigh. Concomitantly, laboratory studies showed that skin could be transplanted between litter mates but not between animals from different litters of the same parentage; this suggested that it should be possible to transplant kidneys between individuals with the same genetic inheritance without rejection occurring. This led Murray et al in Boston in 1954 to carry out the first kidney transplant operation between identical twins.'6 The kidney survived for eight years until recurrence of the original nephritis led again to renal failure. Over the next five years transplantation between identical twins was carried out in several centres in Europe and America. Some failed for technical reasons but in none was there evidence of rejection. The first transplant in Belfast was in 1962 between identical twins: it was a technical failure. About this time Scribner described the semi-permanent arteriovenous shunt which allowed patients to be kept alive by repeated haemodialysis until a kidney became available for transplantation,17 an important development which greatly facilitated the growth of a renal transplant programme. Immunosuppression It is obvious that few patients reaching end -stage kidney failure are fortunate enough to have an identical twin able and willing to provide a kidney. The question wascould rejection be prevented when the graft was taken from a less closely related individual? Total body irradiation as a means of immunosuppression was used prior to kidney transplantation in Boston and Paris between 1958 and 1960. In Boston one out of 12 survived, a transplant from a nonidentical twin, and in Paris a sibling graft succeeded. These results indicated that immunosuppression could work; the problem now was to find the most appropriate methods and regimens. Schwartz and Dameshek in Boston reasoned that an anti-cancer drug such as 6mercaptopurine might be used for immunosuppression and found that rabbits treated with this drug had little response to injection of foreign protein. 18 This led Calne in London to use this drug in kidney transplants in dogs with success, though the drug was very toxic. 19 Calne then went to work in Boston and in 1960 tried out new derivatives of 6 -mercaptopurine which were produced by Hitchings of Burroughs Wellcome in New Jersey. One of these, later known as azathioprine or Imuran, proved in dog kidney transplants to be even more immunosuppressive as well as less toxic than the parent drug.20 In 1960-61, 6-mercaptopurine was used for human grafts in London by Hopewell, 2' in Boston by Murray and Caine, and in Paris by KOss. 22 The only success was Kuiss's patient who also received irradiation and intermittent prednisone. Murray and Caine used azathioprine in 1962: their third case succeeded, and despite several rejection episodes function continued for two years. Azathioprine then became generally accepted as the main immunosuppressive drug for transplantation for the next two decades. In 1962 Goodwin reported successful treatment with steroids of several rejection episodes in a mother-to -child transplant, although the recipient finally died from sepsis.23 After this, the combination of azathioprine and steroid was accepted as standard for kidney transplantation. The general view at that time seems to have been 'the more steroid the better', because this often permitted long -term survival of kidney grafts, even though many patients died from infection: some nephrologists preferred for their patients the greater safety of dialysis in spite of the less good quality of life. Nevertheless, the age of drug immunosuppression had arrived: the search was now on for an optimum regime. Attempts were made by Woodruff24 in Edinburgh and Starzl25 in the USA to develop a more specific weapon, antilymphocyte serum. This was produced in horses by immunising them against peripheral blood lymphocytes, the cells which infiltrate rejecting grafts. The antiserum has promising results in animals but, on the whole, has proved disappointing in human transplantation. The antilymphocyte serum has been purified to antilymphocyte globulin (ALG), the spleen, thymus, or cultured lymphoblasts being used as the source of antigen. Horse serum often produces reactions in patients and so small animals are preferred, especially rabbits, though this greatly increases costs as each batch of serum must be standardised and can only be tested in primates. ALG given along with azathioprine and prednisolone is restricted to the early postoperative period. It is now widely used in North America and in many European centres for treatment of rejection episodes, but is little used in the United Kingdom. It is associated with a high death rate due to opportunistic infections such as cytomegalovirus infection, pneumocytosis, and toxoplasmosis. Rubin from Boston, addressing the spring meeting of the British Transplantation Society in April 1986, attributed the high death rate to the ALG rather than the accompanying steroid. He also considers that the combination of ALG with any other immunosuppressant greatly increases the risk of malignant tumours. The recognition of these risks has been tardy.
From 1962 onwards Hamburger used tissue typing based on lymphocytes it had long been realised that red cell compatibility was essential, and, if transgressed, immediate rejection was the rule.26 Kissmeyer -Nielsen introduced the direct crossmatch between the serum of the recipient and the cells of the donor in 1966, which must of course be negative.27 ( The Ulster Medical Society, 1987.
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The Ulster Medical Journal At the end of 1968 in Belfast we began to transplant cadaver kidneys using the combination of low dose steroid with azathioprine,28, 29 From the beginning we were able to achieve two -year graft survival rates of over 80 per cent, well above all other centres, and we can fairly claim to have been the first to demonstrate that high doses of steroid were unnecessary and that the numerous steroid toxic effects can largely be avoided. Furthermore, most patients escape Cushingoid changes on our low dosage. Blood transfusion from third party donors carries the risk of sensitisation of the recipient against antigens present in the subsequent kidney donor. By the end of the sixties the risk of producing cytotoxic antibodies led to a very cautious approach to giving blood transfusions to patients who might be candidates for renal transplantation. Eventually it was considered desirable to avoid giving any blood transfusions at all. This policy, far from improving the results of transplantation, paradoxically led to lower graft survival rates. This was not at first attributed to the no-transfusion policy, but in 1974 Opelz and Terasaki reported that graft survival was better in patients who had received transfusions than in those not given blood. 30 The conclusion was not generally accepted and their report was criticised on the grounds that it was a multicentre study with many other differences in management besides transfusion. Over the next few years, however, studies in animals, including rhesus monkeys, showed convincingly that blood transfusion improved graft survival in most animals though a few were sensitised and lost their grafts early on. Subsequently, this improvement in graft survival with blood transfusion has been demonstrated in human recipients. There is, however, no doubt that some subjects will develop antibodies and unfortunately there is no way of identifying them in advance. Despite intensive research we still do not understand how transfusion actually benefits transplants and in the absence of a theoretical model we are uncertain as to the best way to use transfusion. The next development in immunosuppression took place after 1970. In 1972 at the Sandoz Laboratories in Basle, Borel found that cyclosporin A, a fungal agent, has potent immunosuppressant activity both in vitro and in viVo,31 and Caine and White in 1976 -78 used it in dog kidney and pig heart transplants with excellent graft survival. The drug was first used for human transplants by Calne in Cambridge in 1978:32 he used it without steroid and considered the main advantage to be the avoidance of steroid side effects. Despite this view many centres now use steroids with cyclosporin A, sometimes in fairly low dose but often in doses high by our standards. Cyclosporin A is now the most widely used immunosuppressant drug in transplantation, not just for kidney but for all types of organ and bone marrow transplantation. Cyclosporin A is not used at present for kidney transplantation in Belfast. In the first place we have consistently attained a one and two year graft survival rate of over 80% for cadaver grafts, and 95% for live donor graftsamong the best experienced at any centre.33 Only by 1986 have some centres equalled our performance. It has serious side effects more numerous than the leucopenia and neoplasia associated with azathioprine. Two of these are of overwhelming importance, nephrotoxicity and lymphoma. The former is dose-related and is exceedingly common, occurring not only in transplanted kidneys but in normal kidneys of patients given the drug for heart or bone marrow transplantation. It is difficult to make aT clinical distinction between transplant rejection and nephrotoxicity and even experienced renal pathologists sometimes find it impossible to make a cytological diagnosis on biopsy appearances. Blood cyclosporin A levels may be of help but toxicity and blood levels do not correlate at all closely. The distinction, however, is very important because if the decline in function is due to toxicity it should improve when the dose is reduced. It was originally thought that cyclosporin A toxic change was completely reversible, but interstitial fibrosis in cyclosporin A -treated grafts has been reported from many centres; Myers and colleagues in 1984 reported reduced glomerular filtration rate in heart transplant patients treated with cyclosporin A, two of whom developed end -stage renal failure, the kidneys showing interstitial fibrosis with focal glomerular sclerosis.34 Experience on the long -term survival of cyclosporin A grafts will soon become available. Our own experience with azathioprine in the long -term is shown in the Table. Our first 100 grafts were done over ten years ago. Ninety-seven were cadaver grafts, three were from living related donors. Forty-seven patients survive with functioning grafts for ten to over 17 years. Twentyone died with wellfunctioning grafts between six months and 15 years after transplant. There were two early deaths with functioning grafts. Thirty grafts have failed (not due to death) over the whole period of 16 years. The second important side effect of cyclosporin A is lymphoma. The earliest cases reported by Calne occurred within a few months, and there were four in the first 32 patients, which he attributed to the large dose used.32 Other centres reporting lymphomata also used quite high doses, though less than Cambridge did initially. Much lower doses are now being used; some centres have switched to azathioprine and steroid after two to six months on cyclosporin treatment but some grafts have been lost from rejection at the change -over. The incidence of neoplasia at the more recent, lower doses is not yet known. Neoplasia of course also occurs with azathioprine: one of our patients died of acute monoblastic leukaemia, two have developed basal cell carcinoma, and seven squamous carcinoma. I am all too uneasily aware that we have given too much azathioprine in the past and we now reduce it for long -term grafts. Other immunosuppressants have been tested: for example, monoclonal antibodies which are more specific forms of ALG have been used in human transplantation, but although early reports by Cosimi were exciting they seem to be more helpful in the laboratory than for clinical situations. 35 Total lymphoid irradiation, pioneered by Myburgh in Johannesburg using baboons,36 utilises irradiation of an inverted Y area of the body similar to that used for treatment of Hodgkin's disease, but, when used for human transplantation, mortality is high.
Triple therapy (cyclosporin A, steroid and azathioprine) or even quadruple therapy (cyclosporin A, steroid, azathioprine and ALG) have been tried in several centres on small series of patients but so far with equivocally significant results. There is no strong evidence that cyclosporin A is superior to the Belfast regimen of azathioprine plus steroid. Eurotransplant reported in October 1985 a first cadaver graft of 82 % at one year using cyclosporin A, a result no better than our own. Furthermore, all methods of immunosuppression have serious side effects and are less than fully effective. The great hope is that a better derivative of cyclosporin A may be obtained, but the analogues cyclosporin B, C, D, E and F are not immunosuppressive, and while G is immunosuppressive, its side effects are not yet known. Developments in tissue typing have taken place over the past twenty years and have led to the settingup of collaborative organisations for exchange of kidneys to obtain better matching -UK Transplant, Eurotransplant and Scandiatransplant all exist for this purpose, and there are links between the three computers so that rare genotypes can be matched. The exchange of kidneys has been facilitated by improvements in harvesting cadaver transplantsbetter perfusion fluids, in situ perfusion, and acceptance of the concept of heart-beating braindead donors.
OPINION I have used kidney transplantation throughout as a model. Except for tissue typing, all these aspects are relevant to other organ transplants. ABO matching alone is used for liver, heart, and heartlung grafts because there is no satisfactory artificial method of replacement of these organs equivalent to dialysis: if a graft cannot be found quickly, the patient will die. Besides the technical difficulties of transplanting a liver, heart or heart-lung preparation there are some special constraints. The donor organ is needed urgently as the patient is already in advanced organ failure when selected. Only patients aged less than 45 are considered (we have successful kidney transplants up to the age of 71), and the donor must be young, certainly less than 35, and matched for size with the recipient. Furthermore, in heart-lung transplantation, the donor must be in the same hospital as the recipient and this raises the problem of moving a dying patient. But in spite of these additional problems remarkably good results have been obtained with heart, liver and, very recently, with heartlung transplantation. The results with the pancreas are, however, less satisfactory for there is the special problem of dealing with its exocrine function, and in the human it has not yet proved possible to transplant separated Islets of Langerhans. It has become fashionable to knock 'hi -tech' medicine, deriding it for syphoning scarce resources from other areas of health care for the benefit of a few. Organ transplantation is the acme of 'hi -tech' medicine, but it is indeed a very real advance. Chronic renal failure is no respecter of persons and occurs. from early childhood to old age. Less than 25 years ago it was a death sentence, a more certain one than even cancer or leukaemia, for which some form of treatment was often possible. As an example I can cite the case of Anna, who developed endstage renal failure at the age of 16. She had two spells of haemodialysis, separated by a transplant which functioned for about three years, during which her daughter, Julie, was born. Two years after a second transplant Sean was born and Anna had a third child in November 1985. Without the derided 'hi-tech' medicine arid the years of patient, constructive and innovative research which has made it possible and which might indeed make many other life-saving developments possible also, Anna would have died at sixteen instead of being a lovely and fulfilled young woman. Despite these arguments transplantation does produce real dilemmas because resources are insufficient to permit treatment of all who might benefit.37 How to decide who should have treatment? That is the question. Many more patients could be treated even with our present restricted facilities if there were more kidney donors. We know, and you know, that many suitable donors are lost, and this is not entirely due to reluctance of the public to allow organ donation. Doctors have a responsibility also. Transplantation doctors have discussed whether legislation might help, particularly an 'opting -out' schemethat is, that it is for the individual to register an objection to donation if he has one, and if no such objection is registered permission is assumed. Manchester has tried 'opting -in' by registering willingness to donate on a computer connected to the intensive care units in the area, but after two years only 200,000 have registered whereas 1,000,000 would be needed to be useful. Some States in the USA have introduced legislation to make it compulsory to request donation before turning off life support machines. Neither 'opting -out' nor 'opting -in' appears so far particularly helpful but the USA scheme is reported to have increased the numbers of donors.
